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Abstract
Introduction: Obesity is an increasingly common comorbidity in critically ill patients. Whether obesity alters sepsis
outcome, susceptibility, treatment, and response is not completely understood.
Methods: We conducted a retrospective analysis comparing three group of septic shock patients based on the
intervals of actual body mass index (BMI) in patients enrolled in the VASST (Vasopressin and Septic Shock Trial)
cohort. Primary outcome measurement was 28-day mortality. We tested for differences in patterns of infection by
comparing the primary site of infection and organism. We also compared the treatments (fluids and vasopressors)
and inflammatory response, measuring adipose tissue-related cytokine concentrations (interleukin [IL]-6, monocyte
chemotactic protein [MCP]-1, tumor necrosis factor [TNF]-a, and resistin) in plasma in a subset of 382 patients. Of
the 778 patients in VASST, 730 patients who had body weight and height measurements were analyzed. Patients
with BMI <25 kg/m2 (n = 276) were grouped as a reference and compared to ‘overweight’ (25< BMI <30 kg/m2,
n = 209) and ‘obese’ (BMI ≥30 kg/m2, n = 245) patients.
Results: Obese patients had the lowest 28-day mortality followed by overweight patients while patients with BMI
<25 kg/m2 had the highest mortality (p = 0.02). Compared to the patients with BMI <25 kg/m2, obese and
overweight patients also had a different pattern of infection with less lung (obese 35%, overweight 45%, BMI<25
kg/m2 50%, p = 0.003) and fungal infection (obese 8.2%, overweight 11%, and BMI<25 kg/m2 15.6%, p = 0.03). Per
kilogram, obese and overweight patients received less fluid during the first four days (p<0.05) and received less
norepinephrine (obese 0.14, overweight 0.21, BMI <25 kg/m2 0.26 µg/kg/min, p<0.0001) and vasopressin (obese 0.28,
overweight 0.36, BMI <25 kg/m2 0.43 µU/kg/min, p<0.0001) on day 1 compared to patients with BMI <25 kg/m2.
Obese and overweight patients also had a lower plasma IL-6 concentration at baseline (obese 106 [IQR 34-686],
overweight 190 [IQR 44-2339], BMI <25 kg/m2 235 [IQR 44-1793] pg/mL, p = 0.046).
Conclusions: Overall obesity was associated with improved survival in septic shock and differences in pattern of
infection, fluids, and vasopressors. Importantly, the magnitude of inflammatory IL-6 response is muted in the obese.
Introduction
Obesity is a major health problem and is the sixth most
important risk factor contributing to overall burden of dis-
ease worldwide [1]. Acute infection coupled with the
immune response (sepsis) has been linked in multiple ways
to obesity [2,3]. Obese patients were over-represented
among those with serious lung injury requiring life support
during the H1N1 viral pandemic [3,4], and the risk of
wound infections is increased in the obese following major
surgery [5]. It has also been suggested that obesity itself is
a chronic inflammatory condition with increased circulat-
ing pro-inflammatory cytokines at rest [6,7]. Despite the
apparent risk factors associated with obesity, it appears that
in small case series obese critically ill patients, the majority
of whom have severe infection, may fare better than those
of normal weight [8,9]. Whether there is a true relationship
between obesity and sepsis-induced morbidity and mortal-
ity remains unclear [10,11].
We conducted a retrospective analysis of the Vasopres-
sin and Septic Shock Trial (VASST) [12] to help determine
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whether being overweight or obese altered (a) mortality
and organ dysfunction outcomes of sepsis, (b) pattern of
susceptibility to infection, (c) treatment received by
patients, or (d) the inflammatory response to sepsis. To
explore an inflammatory response of obese and over-
weight, compared with lean patients, during the initial
phase of septic shock, it is well known that adipose tissues
produce and release a number of pro-inflammatory media-
tors, including cytokines and chemokines, such as inter-
leukin-6 (IL-6) [6,13], monocyte chemotactic protein-1
(MCP-1) [14], and tumor necrosis factor-alpha (TNF-a)
[15], as well as the adipokine resistin [16]. Therefore, we
assayed these cytokines at study enrollment in conveni-
ence samples of patients with septic shock in our cohort.
Materials and methods
Patients
We conducted a retrospective analysis in patients enrolled
in a cohort of septic shock, the VASST. The VASST is a
multicenter, randomized, double-blind, controlled trial
evaluating the efficacy of vasopressin versus norepinephr-
ine on mortality in 778 patients with septic shock [12].
Septic shock was defined by the presence of two or more
diagnostic criteria for systemic inflammatory response syn-
drome (SIRS), proven or suspected infection, at least one
new organ dysfunction by Brussels criteria, and hypoten-
sion despite adequate fluid resuscitation [17,18]. Of these,
730 patients had body weight and height measured at the
time of enrollment of the VASST (typically about 11
hours after they first developed septic shock), and body
mass index (BMI) was calculated as weight (in kilograms)
divided by height (in meters) squared. Since our cohort
had a small number of underweight (BMI of less than 18.5
kg/m2, n = 26) patients and these patients had similar out-
comes in crude analysis compared with patients classified
as normal BMI (18.5 to 24.9 kg/m2, n = 250), we used a
modified form of the BMI categories endorsed by the
National Institutes of Health [19], in which subjects with a
BMI of less than 25 kg/m2 were grouped together (n =
276) and were compared with 209 patients classified as
overweight (BMI 25 to 29.9 kg/m2) and 245 patients clas-
sified as obese (BMI of at least 30 kg/m2). The VASST
protocol was approved by the research ethics boards of all
participating centers, and written informed consent was
obtained from all patients or their relatives. The institu-
tional review board for the VASST is the University of
British Columbia-Providence Health Care (UBC-PHC)
Research Ethics Board, and the approval number is H06-
50080.
Baseline clinical phenotype measurements
Baseline characteristics of the patients were measured at
study enrollment and included age, gender, and pre-
existing conditions identified on the basis of patients’
medical history. Hemodynamic variables (mean arterial
pressure, central venous pressure (CVP), and heart rate),
tidal volume (in patients who received mechanical venti-
lation at study enrollment; BMI of less than 25 kg/m2 n =
172, overweight n = 143, and obese n = 160), and base-
line laboratory variables (lactate, creatinine, white blood
cell count, and platelet count) were also measured.
Outcome measurements
Our primary outcome measurement was 28-day mortal-
ity. Secondary outcomes were organ dysfunctions as pre-
viously described [20]. To assess organ dysfunction and
to correct organ dysfunction scoring for deaths in the
28-day observation period, we calculated days alive and
free of organ dysfunction. During each 24-hour period
(8 a.m. to 8 a.m.) for each variable, days alive and free
was scored as 1 if the patient was alive and free of
organ dysfunction (normal or mild dysfunction using
the Brussels criteria [18]). Days alive and free was scored
as 0 if the patient had organ dysfunction (moderate or
worse) or was not alive. Every day over the 28-day
observation after intensive care unit (ICU) admission
was scored in this way. Thus, the lowest score possible
for each variable was 0 and the highest score possible
was 28. A low score indicates more organ dysfunction,
whereas a high score indicates less organ dysfunction.
Pattern of infection
Infection was defined as culture positivity that was
judged by the attending clinician of each study site to
be an infection rather than just colonization. Pathogens
were identified by the culture from the primary site of
infection.
Treatment
The amount of infused fluid is associated with hospital
outcome [21,22]; therefore, we also tested for differences
in the amount of fluid intake, output, and accumulated
net fluid balance during the first four days after ICU
admission (or study enrollment). We also tested for differ-
ences in infusion rates of vasopressor medications, which,
in this study, were primarily norepinephrine and vasopres-
sin. We measured serum vasopressin levels in the over-
weight and obese patients receiving vasopressin infusion
and compared that vasopressin level with that of patients
with a BMI of less than 25 kg/m2. Of 396 patients in the
vasopressin treatment group, 54 patients had measure-
ment of serum vasopressin level over time (baseline and 6,
24, and 72 hours) and received vasopressin infusion. Of
these, 46 patients had BMI measurements and were classi-
fied as having a BMI of less than 25 kg/m2 (n = 17) or
being overweight (n = 13) or obese (n = 16) and were
included in this analysis. The protocol for serum vasopres-
sin level measurement was previously described [12].
Wacharasint et al. Critical Care 2013, 17:R122
http://ccforum.com/content/17/3/R122
Page 2 of 10
Inflammatory cytokine response
We assayed cytokines that have also been related to adi-
pose tissue, including IL-6 [12], MCP-1 [13], TNF-a
[14], and resistin [15], in 138 patients with a BMI of less
than 25 kg/m2, 112 overweight patients, and 132 obese
patients at enrollment. Briefly, whole-blood samples
were drawn into chilled 7-mL EDTA Vacutainer tubes
(BD, Mississauga, ON, Canada), put on ice immediately,
and spun at 3,000 revolutions per minute for 15 minutes
and then plasma was collected and stored at −70°C until
further use [12]. Human 39-plex kits (EMD Millipore,
Billerica, MA, USA) were used in accordance with the
recommendations of the manufacturer with modifica-
tions as described below. Briefly, samples were mixed
with antibody-linked magnetic beads on a 96-well plate
and incubated overnight at 4°C with shaking. Plates
were washed twice with wash buffer in a BioTek ELx405
washer (BioTek, Winooski, VT, USA). After 1-hour
incubation at room temperature with biotinylated detec-
tion antibody, streptavidin-phycoerythrin was added for
30 minutes with shaking. Plates were washed as above,
and phosphate-buffered saline was added to wells for
reading by using a Luminex 200 (Illumina Inc., San
Diego, CA, USA) with a lower bound of 100 beads per
sample per cytokine. Each sample was measured in
duplicate.
Statistical analysis
We tested for the differences in baseline characteristics
between the three groups of patients (obese, overweight,
and patients with a BMI of less than 25 kg/m2) by using
a Kruskal-Wallis test for continuous data or a chi-square
test for categorical data, and we report the median and
interquartile range (IQR). We evaluated the primary
outcome variable (28-day mortality) by using log-rank
(Mantel-Cox) test to compare Kaplan-Meier curves for
patients with a BMI of less than 25 kg/m2, overweight
patients, and obese patients. The risk of 28-day hospital
mortality was expressed as hazard ratio (HR) with 95%
confidence interval (CI). We tested for the influence of
covariates, including APACHE II (Acute Physiology and
Chronic Health Evaluation II) score, gender, diabetes
history, lung infection, fungal infection, and BMI by
using Cox regression analysis. Secondary clinical out-
comes were days alive and free of organ dysfunction
(including cardiovascular, respiratory, renal, hepatic, neu-
rologic, and coagulation), days alive and free of SIRS (two
of four SIRS criteria), and days alive and free of artificial
organ support (including mechanical ventilation and
hemodialysis). We tested for differences in the site of
infection and the frequency of Gram-positive, Gram-
negative, or fungal infection by using a chi-square test.
We tested for differences in fluid amount and vasopres-
sor administration dosages by using a Kruskal-Wallis
test. We tested for differences in the vasopressin concen-
tration over time by using one-way repeated-measures
analysis of variance, and we report the mean and stan-
dard error of the mean. Serum cytokine concentrations
of three patient groups were analyzed by using a Kruskal-
Wallis test, and we report the median and IQR. Differ-
ences were considered significant by using a two-tailed
P value of less than 0.05. Analyses were performed by
using SPSS (version 17.0; IBM Corporation, Armonk,
NY, USA) statistical software packages.
Results
Baseline characteristics
The median BMIs of the patients with a BMI of less than
25 kg/m2, overweight patients, and obese groups were 23,
28, and 34 kg/m2, respectively. At initial presentation, the
obese group - compared with the other two patient
groups - least frequently had male patients (obese 55.5%,
overweight 67.9%, BMI of less than 25 kg/m2 62%; P =
0.03), most frequently had diabetes (obese 29.8%, over-
weight 20.6%, BMI of less than 25 kg/m2 14.9%; P <
0.0001), had the highest CVP value (obese 15 mm Hg,
overweight 14 mm Hg, BMI of less than 25 kg/m2
14 mm Hg; P = 0.002), had the highest serum creatinine
concentration (obese 191 µmol/L, overweight 150 µmol/
L, BMI of less than 25 kg/m2 130 µmol/L; P < 0.0001),
and was mechanically ventilated with a highest tidal
volume per kilogram of predicted body weight [23]
(obese 9.3 mL/kg, overweight 8.8 mL/kg, BMI of less
than 25 kg/m2 8.3 mL/kg; P < 0.0001) on enrollment.
There were no differences in age, APACHE II severity
score, or other laboratory variables and calculations at
baseline, including serum lactate and glomerular filtra-
tion rate, across the three patient groups (Table 1).
Obese and overweight patients with septic shock have
lower 28-day mortality and less organ dysfunction than
patients with a BMI of less than 25 kg/m2 despite
similar severity at presentation
We found that the obese and overweight patients had sig-
nificantly lower 28-day mortality compared with those
with a BMI of less than 25 kg/m2 (P = 0.02) (BMI of less
than 25 kg/m2 versus overweight, P = 0.10; BMI of less
than 25 kg/m2 versus obese, P = 0.01; overweight versus
obese, P = 0.2) (Figure 1). We introduced BMI as a contin-
uous variable in our regression model to validate our
hypothesis, following adjustment for factors that are
known to influence mortality (APACHE II score) and that
differ between groups at enrollment (gender, pre-existing
diabetes, lung infection and fungal infection). We found
that for every 1-unit increase in BMI, the HR-adjusted
mortality was 2% lower (95% CI 0.97 to 0.99, P = 0.04)
(Table 2). We also found that obese and overweight
patients had significantly lower coagulation dysfunction
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(obese 28, overweight 23, and BMI of less than 25 kg/m2
21 days alive and free of dysfunction; P <0.0001) and SIRS
(obese 8, overweight 7, and BMI of less than 25 kg/m2 4
days alive and free of two of four SIRS criteria; P = 0.02)
compared with those with a BMI of less than 25 kg/m2.
Differences in other organ dysfunctions were not signifi-
cantly different across the three patient groups. There
were no differences in days alive and free of mechanical
ventilation (obese 11, overweight 10, BMI of less than 25
kg/m2 6 days; P = 0.36) and days alive and free of renal
replacement therapy (obese 25, overweight 24, BMI of less
than 25 kg/m2 24 days; P = 0.93) among the three patient
groups.
Pattern of infection
Compared with patients with a BMI of less than 25 kg/m2,
obese and overweight patients had a significantly lower
rate of lung infection (obese 35%, overweight 45%, and
BMI of less than 25 kg/m2 49.8%; P = 0.003) as the source
of their severe sepsis and had significantly fewer fungal
Table 1 Baseline characteristics compared on the basis of actual body mass index category in three groups of patients
with septic shock
Baseline characteristics Actual body mass indexa category, kg/m2 P value
BMI <25
(n = 276)





Age, years 63 (48-74) 64 (50-73) 63 (53-72) 0.62
Gender: Male, number (percentage) 171 (62) 142 (67.9) 136 (55.5) 0.03b
Race: Caucasian, number (percentage) 231 (83.7) 177 (84.7) 209 (85.3) 0.88
Body mass indexa, kg/m2 23 (20-24) 28 (26-29) 34 (32-39) <0.0001b
Severity of illness
APACHE II score 27 (21-32) 26 (22-31) 27 (23-32) 0.51
Surgical condition, number (percentage) 52 (18.8) 45 (21.5) 58 (23.7) 0.4
In-hospital steroid treatment, number (percentage) 211 (76.7) 167 (79.9) 172 (70.8) 0.07
Pre-existing conditions, number (percentage)
Chronic obstructive pulmonary disease 44 (15.9) 31 (14.8) 41 (16.7) 0.86
Congestive heart failure 19 (6.9) 14 (6.7) 22 (9.0) 0.57
Chronic liver disease 27 (9.8) 30 (14.4) 26 (10.6) 0.26
Chronic renal failure 29 (10.5) 24 (11.5) 27 (11) 0.94
Diabetes 41 (14.9) 43 (20.6) 73 (29.8) <0.0001b
Ischemic heart disease 40 (15.4) 38 (20) 50 (21.8) 0.18
Chronic steroid use 67 (24.3) 42 (20.1) 51 (20.8) 0.48
Hemodynamic variables at day 1
Central venous pressure, mm Hg 14 (10-17) 14 (11-18) 15 (12-18) 0.002b
Mean arterial pressure, mm Hg 55 (50-60) 56 (51-61) 55 (49-61) 0.09
Heart rate, beats per minute 130 (115-144) 125 (112-140) 125 (106-140) 0.05
Mechanical ventilation variables at day 1
Tidal volume, mL 530 (450-630) 570 (480-650) 571 (490-650) 0.03b
Tidal volume, mL/kg of PBWc 8.3 (7.0-9.7) 8.8 (7.4-10.3) 9.3 (7.9-10.8) <0.0001b
Laboratory variables at day 1
White blood cells, x103/mm3 14.5 (6.7-21.8) 13.1 (8.0-19.2) 12.8 (7.4-20.2) 0.72
Platelets, x103/mm3 145 (55-256) 144 (72-232) 165 (90.5-254.5) 0.13
Creatinine, µmol/L 130 (80-218) 150 (104-266) 191 (120-297) <0.0001b
GFR, mL/minute 44 (26-76) 45 (25-72) 47 (29-77) 0.27
Lactate, mmol/L 2.0 (1.2-4.2) 2.1 (0.9-3.8) 1.7 (1.1-3.5) 0.27
PaO2/FiO2 180 (120-255) 182 (123-255) 190 (135-259) 0.41
Data are presented as median (interquartile range) for continuous variables. P values were calculated for statistical difference between three patient groups with
the use of chi-square test and Kruskal-Wallis test. aBody mass index (BMI) was measured at enrollment of the Vasopressin and Septic Shock Trial (average about
11 hours after onset of septic shock). bP <0.05. cPredicted body weight (PBW) (male: 50 + 0.91 (centimeters of height: 152.4), female: 45.5 + 0.91 (centimeters of
height: 152.4)). APACHE II, Acute Physiology and Chronic Health Evaluation II; GFR, glomerular filtration rate (Cockcroft-Gault formula); PaO2/FiO2, arterial oxygen
partial pressure per fraction of inspired oxygen.
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infections (obese 8.2%, overweight 11%, and BMI of less
than 25 kg/m2 15.6%; P = 0.03) (Table 3).
Obese and overweight patients receive less intravenous
fluids and vasopressors than patients with a BMI of
less than 25 kg/m2
The updated Surviving Sepsis Campaign guidelines sug-
gest titrating fluid therapy to body mass with an initial
prescription of at least 30 mL/kg [24]. Further mass-
adjusted fluid administration is prescribed as required. It
is now appreciated that, whereas adequate early fluid
resuscitation is crucial, overzealous fluid administration
is harmful [21,22]. During the initial resuscitation for
septic shock, obese and overweight patients received sig-
nificantly less fluids per kilogram than those with a BMI
of less than 25 kg/m2 (Table 4). This appears driven by
non-body weight-adjusted fluid prescription, because
there was no significant difference in absolute fluid
administered between groups (Table 4). Although vaso-
pressin is traditionally prescribed without body weight
adjustment, some have suggested that vasopressin be pre-
scribed with it [25]. During the initial phase of septic
shock (day 1), both norepinephrine (obese 0.14, IQR 0.09
to 0.25; overweight 0.21, IQR 0.12 to 0.34; BMI of less
than 25 kg/m2 0.26, IQR 0.15 to 0.44 µg/kg per minute;
P < 0.0001) and body weight-adjusted vasopressin (obese
0.28, IQR 0.23 to 0.33; overweight 0.36, IQR 0.31 to 0.40;
BMI of less than 25 kg/m2 0.43, IQR 0.38 to 0.50 µU/kg
per minute; P <0.0001) dosage - similar to fluid adminis-
tration - were prescribed at significantly lower doses in
obese and overweight patients compared with those with
a BMI of less than 25 kg/m2. At 72 hours of vasopressin
infusion, obese and overweight patients had a trend
toward lower serum vasopressin level (obese 28.9 ± 7.9,
overweight 51.5 ± 16.5, BMI of less than 25 kg/m2 69.9 ±
17.5 pmol/L; P = 0.08) compared with patients with a
Figure 1 Kaplan-Meier curves of 28-day survival compared by actual body mass index (BMI) across three groups of patients with septic
shock. Obese patients with septic shock had a significantly lowest 28-day mortality following overweight patients, whereas the septic shock patients
with a BMI of less than 25 kg/m2 had a highest 28-day mortality (P = 0.02, log-rank analysis). *P <0.05, compared among three groups.
Table 2 Hazard ratio of 28-day mortality in patients with septic shock
Hazard ratio 95% confidence interval P value
APACHE II score (per score) 1.06 1.05-1.08 <0.0001a
Male 1.12 0.87-1.43 0.39
Diabetes 1.05 0.78-1.41 0.77
Lung infection 1.02 0.79-1.33 0.86
Fungal infection 1.26 0.87-1.82 0.22
BMI (per score) 0.98 0.97-0.99 0.041a
P values were calculated by using Cox regression analysis. aP <0.05. APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass index.
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BMI of less than 25 kg/m2 receiving vasopressin infusion
(Figure 2).
IL-6 levels of obese and overweight patients are muted
compared with those of patients with a BMI of less than
25 kg/m2
There was no significant difference in body temperature
(obese 38.6, IQR 37.8 to 39.4; overweight 38.5, IQR 37.8
to 39.1; BMI of less than 25 kg/m2 38.4, IQR 37.5 to
39.1°C; P = 0.053), platelet count (obese 165,000, IQR
90,500 to 254,500; overweight 144,000, IQR 72,000 to
232,000; BMI of less than 25 kg/m2 145,000, IQR 55,000
to 256,000/mm3; P = 0.13), and white blood cell count
(obese 12,800, IQR 7,400 to 20,200; overweight 13,100,
IQR 8,000 to 19,200; BMI of less than 25 kg/m2 14,500,
IQR 6,700 to 21,800/mm3; P = 0.72) between groups.
Table 3 Pattern of infection of patients with septic shock
Actual body mass index category, kg/m2 P value
BMI <25
(n = 276)




Primary source of infection, number (percentage)
Lung 137 (49.8) 94 (45) 85 (35) 0.003a
Abdomen 69 (25.1) 54 (25.8) 73 (30) 0.41
Genitourinary 10 (3.6) 11 (5.3) 13 (5.3) 0.58
Blood 13 (4.7) 14 (6.7) 16 (6.6) 0.57
Skin 17 (6.2) 14 (6.7) 26 (10.7) 0.12
Otherb 23 (8.4) 21 (10) 25 (10.3) 0.72
Pathogen type in cultures, number (percentage)
Gram-positive 81 (29.5) 53 (25.4) 81 (33.3) 0.18
Gram-negative 68 (24.7) 52 (24.9) 46 (18.9) 0.21
Fungal 43 (15.6) 23 (11) 20 (8.2) 0.03a
aP <0.05. bBone/joint/central nervous system infection. P values were calculated for statistical difference between three patient groups with the use of chi-square
test. BMI, body mass index.
Table 4 Fluid administration during the first four days after septic shock
Amount of fluid, mL Amount of fluid per body weight, mL/kg
BMI <25
(n = 276)




P value BMI <25
(n = 276)





Predicted body weighta, kg 67 ± 2.1 64 ± 0.7 61 ± 1.0 0.003b - - -
Day 1
Intake 11,000 ± 310 10,500 ± 360 10,500 ± 310 0.27 180 ± 5 130 ± 5 100 ± 3 <0.0001b
Output 4,100 ± 200 3,900 ± 240 3,900 ± 190 0.7 60 ± 3 50 ± 3 40 ± 2 <0.0001b
Net accumulated balance 7,000 ± 330 6,600 ± 360 6,700 ± 330 0.43 110 ± 5 84 ± 5 70 ± 3 <0.0001b
Day 2
Intake 16,000 ± 420 15,200 ± 500 15,400 ± 420 0.28 250 ± 7 190 ± 6 150 ± 5 <0.0001b
Output 6,500 ± 270 6,400 ± 320 6,400 ± 290 0.95 100 ± 5 80 ± 4 60 ± 3 <0.0001b
Net accumulated balance 9,500 ± 430 8,800 ± 490 9,000 ± 460 0.28 150 ± 7 110 ± 6 90 ± 5 <0.0001b
Day 3
Intake 19,900 ± 520 19,000 ± 600 19,400 ± 510 0.37 320 ± 9 240 ± 8 190 ± 5 <0.0001b
Output 9,100 ± 360 8,900 ± 410 9,300 ± 410 0.95 140 ± 6 110 ± 5 90 ± 4 <0.0001b
Net accumulated balance 10,800 ± 490 10,200 ± 580 10,200 ± 540 0.31 170 ± 8 130 ± 7 100 ± 5 <0.0001b
Day 4
Intake 23,600 ± 590 23,000 ± 710 23,300 ± 590 0.41 380 ± 10 290 ± 9 230 ± 7 <0.0001b
Output 12,000 ± 430 12,300 ± 530 12,600 ± 530 0.9 190 ± 7 160 ± 7 120 ± 6 <0.0001b
Net accumulated balance 11,700 ± 540 10,700 ± 660 10,700 ± 600 0.17 190 ± 9 140 ± 8 110 ± 6 <0.0001b
Data are presented as mean ± standard error of the mean. P values were calculated for statistical difference between three patient groups with the use of Kruskal-Wallis
test. aPredicted body weight (male: 50 + 0.91 (centimeters of height: 152.4), female: 45.5 + 0.91 (centimeters of height: 152.4)). bP <0.05. BMI, body mass index.
Wacharasint et al. Critical Care 2013, 17:R122
http://ccforum.com/content/17/3/R122
Page 6 of 10
We found that, in the early phase of septic shock, plasma
IL-6 (obese 106, IQR 34 to 686; overweight 190, IQR 44 to
2,339; BMI of less than 25 kg/m2 235, IQR 44 to 1,793 pg/
mL; P = 0.046) levels were significantly lower in obese and
overweight patients than in those with a BMI of less than
25 kg/m2 (Figure 3). There was no difference in plasma
MCP-1 (obese 567, IQR 220 to 1,817; overweight 842, IQR
284 to 2,386; BMI of less than 25 kg/m2 782, IQR 315 to
2,686 pg/mL; P = 0.06), resistin (obese 77, IQR 39 to 137;
overweight 66, IQR 37 to 134; BMI of less than 25 kg/m2
73, IQR 38 to 134 ng/mL; P = 0.85), or plasma TNF-a in
obese or overweight patients versus those with a BMI of
less than 25 kg/m2 (obese 15, IQR 6 to 29; overweight
14, IQR 7 to 31; BMI of less than 25 kg/m2 13, IQR 6 to
33 pg/mL; P = 0.86).
Discussion
Our major finding was that despite equal severity of ill-
ness upon presentation, mortality in obese and over-
weight patients was significantly lower than in patients
with a BMI of less than 25 kg/m2 (Figure 1). Compared
with those with a BMI of less than 25 kg/m2, obese and
overweight patients had less frequent lung and fungal
infections as the site and organism causing septic shock.
We also found that obese and overweight patients were
treated differently, in what appeared to be a ‘one size fits
all’ non-weight-adjusted dosing, so that obese and over-
weight patients received less fluids and vasopressors per
kilogram (norepinephrine and vasopressin) than patients
with a BMI of less than 25 kg/m2. Unlike previous
reports of obesity augmenting the inflammatory response
[6,7,13], we found that the IL-6 inflammatory response
was muted in overweight and obese patients compared
with those with a BMI of less than 25 kg/m2 in early sep-
tic shock. This surprising result is novel and consistent
with current and previous reports of improved survival
outcomes in obese patients [8,9].
Figure 2 Serum vasopressin level during septic shock compared across the three patient groups. At 24 and 72 hours after vasopressin
infusion, the overweight and obese patients had a trend toward lower mean vasopressin concentrations compared with those with body mass
index (BMI) of less than 25 kg/m2 (P = 0.08, one-way repeated-measures analysis of variance). Error bars indicate standard error of the mean.
Figure 3 Plasma interleukin-6 (IL-6) expression differences at
the initial phase of septic shock compared across the three
patient groups. Compared with patients with a body mass index
(BMI) of less than 25 kg/m2, overweight and obese patients had
significantly lower IL-6 (P = 0.046) plasma levels at the initial phase
of septic shock. P values were calculated by using the Kruskal-Wallis
test. Error bars indicate interquartile range. *P <0.05.
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Conceivably, the inclusion of very underweight or very
overweight patients could alter this analysis and inter-
pretation. We removed the underweight group (n = 26)
and re-analyzed for mortality difference and found the
same significant result in which obese patients had the
lowest 28-day mortality followed by overweight and nor-
mal-BMI patients. A similar post hoc analysis of the
morbidly obese (BMI ≥40 kg/m2) showed that this
group had a lower 28-day mortality than all other
weight groups, consistent with a previous report by
Abhyankar and colleagues [26]. We also found that
despite a higher prevalence of diabetes, those with obe-
sity had a decreased risk of hospital mortality. Covariate
adjustment of diabetes appeared to augment this protec-
tion for the obese. We found that BMI was an indepen-
dent predictor of lower mortality with an HR of 0.98
per kg/m2 (95% CI 0.97 to 0.99, P = 0.041), suggesting
that although diabetics had a poorer prognosis, diabetes
itself had a weaker association with mortality than BMI
(Table 2). Our results are in agreement with data from
the Acute Decompensated Heart Failure National Regis-
try, which studied patients with acute heart failure and
found that hospital mortality rates decreased in a near-
linear fashion across higher BMI. For every 5-unit
increase in BMI, the odds of risk-adjusted mortality
were 10% lower (95% CI 0.88 to 0.93, P < 0.0001) [10].
Our findings also align with a meta-analysis in critically
ill patients which demonstrated that patients who were
obese (had a BMI of 30 to 39.9 kg/m2) had significantly
lower mortality compared with the non-obese patients
(BMI of less than 30 kg/m2) (relative risk 0.86, 95% CI
0.81 to 0.91; P <0.001) [11].
Previous studies demonstrate that low tidal volume
ventilation is associated with a lower mortality [23],
which might have contributed to our findings. However,
we found the opposite. Obese and overweight patients
received higher tidal volume ventilation compared with
patients with a BMI of less than 25 kg/m2, particularly
when corrected to predicted body weight (Table 1).
Although our data do not allow us to determine whether
there was an absolute difference in susceptibility to infec-
tion (since we would need to know the number of obese
and non-obese patients at risk), we did observe a substan-
tial difference in pattern of infection. We observed a large
and significant reduction in the fraction of patients having
lung infections and the fraction of patients having fungal
infections in obese patients. One possible limitation to this
finding is that, in this patient cohort, the diagnosis of lung
infection was based primarily on physician judgment,
which depended on results from chest radiographs and
sputum culture. This could have been confounded by the
increasing inability to obtain clear or definitive chest
radiographs in obese patients. Although there was no sta-
tistically significant difference in white blood cell counts
or a baseline difference in immunosuppression or chronic
steroid use, we did find that obese and overweight patients
expressed significantly lower plasma IL-6 levels during the
initial phase of septic shock compared with those with a
BMI of less than 25 kg/m2. This is in agreement with a
study of patients with blunt injury which found that obese
patients had a significantly lower inflammatory cytokine
profile than those with a normal BMI [27]. Why obese
patients have an altered IL-6 inflammatory response is not
known. However, the finding of decreased circulating IL-6
concentrations in obese patients with sepsis is consistent
with the observation of improved survival outcome. We
also measured resistin, an adipokine that antagonizes the
effects of insulin [16] and that functions as a pro-inflam-
matory cytokine [28]. Unlike in stable obese patients in
whom resistin levels are much higher than those with a
normal BMI, we found no significant difference between
obese and normal-BMI patients in early septic shock.
Unlike in most medical therapies which rely upon
weight-based dosing, we hypothesized that the empirical
manner (1 L of fluid at a time mentality) in which fluid
and vasopressor therapy are recommended for sepsis
[22,24] would cause obese and overweight patients to
receive relatively less weight-adjusted fluids and vaso-
pressors than normal-BMI patients. Alternatively, the
treating physicians may have recognized that blood
volume is not linearly related to weight [29,30] and,
therefore, may have followed the current Surviving Sepsis
Campaign guidelines that suggest that fluid administra-
tion be based on ideal body weight, which did not differ
between the three groups in this study (Table 4). Indeed,
obese and overweight patients received less body weight-
adjusted fluids, norepinephrine, and vasopressin in early
septic shock compared with the patients with a BMI of
less than 25 kg/m2. As excessive fluid and vasopressor
resuscitation is associated with increased mortality
[21,22], it may be that using doses more typically used
for smaller individuals was, ironically, protective. To
directly assess whether this was the case, we measured
vasopressin levels in patients randomly assigned to
receive this drug in the protocolized non-body weight-
adjusted dose used in the VASST. We found that, com-
pared with those with a BMI of less than 25 kg/m2, obese
and overweight patients had a trend toward lower serum
vasopressin concentrations after 24 hours of vasopressin
infusion. The net accumulated fluid balance differs by
only 1 L between patients of normal weight and obese
patients. It could be argued that this small difference is
unlikely to account for the observed outcome differences.
However, indexed to body mass, this amounts to a differ-
ence of 80 mL/kg, a remarkable difference that conceiva-
bly could be related to outcomes. In addition, although
there was a statistically significant difference in CVP
values between the three patient groups, which was
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possibly due to differences in chest wall compliance in
the obese compared with the normal-BMI patients, the
clinical significance of this small difference is uncertain.
The strengths of this study are, first, that our cohort is a
large prospective multicenter cohort of patients with well-
defined septic shock [12]. Second, our results after covari-
ate-adjusted and unadjusted analyses were consistent.
There are several important limitations to our study.
APACHE II score has never been validated in obese
patients. For example, oxygenation may be worsening
despite normal lung function or creatinine level may be
increased despite normal kidney function. Thus, obese
patients may have artificially elevated APACHE II
scores. However, there was no difference of serum lac-
tate levels between the three patient groups at enroll-
ment. Because our analysis was retrospective, some
additional useful data such as coexisting hypertension,
serum cholesterol, or other serum adipokines such as
leptin and adiponectin which regulate insulin sensitivity
were not recorded in the dataset. In addition, adipose
tissue-related cytokines in our analysis are released not
only from adipose tissue but also from other tissues and
this could affect our interpretation. Also, our study may
represent not the ‘real’ population of obese patients with
sepsis but only an obese population included in a rando-
mized controlled study with a strict inclusion criteria.
Conclusions
We demonstrated that, in a cohort of patients with sep-
tic shock, the obese and overweight patients had
decreased mortality compared with patients with a BMI
of less than 25 kg/m2. Obese and overweight patients
may have had less aggressive disease, as shown by our
evaluations of blunted host inflammatory response to
pathogens (lower IL-6), and an altered pattern of infec-
tion (less frequent lung and fungal infection). Obese and
overweight patients may also have been protected by
receiving less fluids and vasopressors compared with the
patients with a BMI of less than 25 kg/m2.
Key messages
• In septic shock, the obese and overweight patients
had decreased mortality compared with patients
with a BMI of less than 25 kg/m2.
• Compared with patients with a BMI of less than
25 kg/m2, obese and overweight patients with sepsis
had a lower rate of lung infection as the source of
their severe sepsis as well as fewer fungal infections.
• In septic shock, the obese and overweight patients
receive less intravenous fluids and vasopressors per
kilogram than patients with a BMI of less than
25 kg/m2.
• At the initial phase of septic shock, plasma IL-6
concentrations in obese and overweight patients are
muted compared with those of patients with a BMI
of less than 25 kg/m2.
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